Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study-Reference-Cited by-同舟云学术

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

Published:2018-02 Issue:2 Volume:13 Page:194-204
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Reck Martin,Taylor Fiona,Penrod John R.,DeRosa Michael,Morrissey Laura,Dastani Homa,Orsini Lucinda,Gralla Richard J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

3. National Comprehensive Cancer Network. NCCN clincal practice guidelines in oncology. Non-small cell lung cancer version 4.2017. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed April 17, 2017.

4. American Cancer Society. Lung cancer (non-small cell). http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. Accessed June 8, 2016.

5. Pointed progress in second-line advanced non–small-cell lung cancer: the rapidly evolving field of checkpoint inhibition;Melosky;J Clin Oncol,2016

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Roles of CircRNA-miRNA Networks in Cancer Development and Therapeutic Response;Non-coding RNA Research;2024-09

2. Patient-reported outcomes in CodeBreak 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation;Lung Cancer;2024-08

3. Comparison of Nivolumab with Docetaxel in the Treatment of Advanced Squamous Cell Non-small Cell Lung Cancer;Journal of Advanced Lung Health;2024-07-16

4. Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma;Scientific Reports;2024-06-27

5. Molecular Markers, Immune Therapy, and Non-Small Cell Lung Cancer—State-of-the-Art Review for Surgeons;Journal of Laparoendoscopic & Advanced Surgical Techniques;2024-06-20